Improving blood product management in placenta accreta patients with severe bleeding: institutional experience
Authors' conclusion
Given no significant morbidity or mortality, clinical judgment in experienced centers appears safe for the management of PAS patients undergoing CS.
Study context
- Population
- Patients with placenta accreta spectrum (placenta accrete spectrum (PAS)) undergoing cesarean section, 2012–2018
- Participants
- 221 patients
- Exposure
- Severe bleeding vs bleeding managed as uncomplicated cesarean section (CS)
- Group 1n = 133
- Group 2n = 88reference
- Outcome
- Peri-operative outcomes
Methodological detailschart review, single-centre
- Chart review
- Single-centre
Main finding
As reported in the abstract
Deaths
0
Disseminated intravascular coagulation
0
ICU admission
five cases (2.2%)
Observational data: associations, not effects.
Original publication
Improving blood product management in placenta accreta patients with severe bleeding: institutional experience. Int J Obstet Anesth. Published 8 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →